novartis-bid-supreme-court-gilenya-patent-fight Pharma Related Topics 
pharmaphorum
OCTOBER 17, 2022
Novartis’ hopes that the Supreme Court would protect its big-selling multiple sclerosis drug Gilenya from generic competition have been dashed. If they do so, Novartis has predicted it will lose $300 million in sales over the remainder of this year. Gilenya made revenues of $2.8
pharmaphorum
SEPTEMBER 21, 2022
Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US. The US Court of Appeals for the Federal Circuit (CAFC) has denied the Swiss pharma group’s petition to rehear its decision on the validity of US Patent No.
Expert insights. Personalized for you.
52 
Let's personalize your content